In vivo, a PAR-2 knockout had no impact on initial liver fibrosis after 5 weeks of CCl4 treatment but prevented the progression of fibrosis with sustained CCl4 treatment after 8 weeks, as reflected by lower hydroxyproline content. The gene discussed is F2RL1; the disease is Hepatic fibrosis.